La Jolla, Calif. (PRWEB) November 12, 2012
CHI-California Healthcare Institute today announced the election of five new executives to its board of directors: Dr. Michael A. Friedman, CEO of City of Hope; Alan J. Malus, executive vice president and president of analytical technologies at Thermo Fisher Scientific; Alberto Mas, worldwide president of BD Biosciences; Heather L. Mason, senior vice president of Abbott Diabetes Care; and Grant Yonehiro, president of Perseid Therapeutics. CHI is a non-profit public policy research and advocacy organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
“From basic research and patient care to data analysis, diagnostics, and therapeutics, these executives represent the excellence and diversity of the biomedical industry, dedicated to advancing the latest treatments, tools and technologies for unmet medical needs,” said CHI President and CEO David L. Gollaher, Ph.D. “They will help guide CHI’s policy agenda in 2013, as we navigate a most challenging fiscal environment and continued industry consolidation.”
The CHI board of directors consists of more than 30 leaders in the California life sciences community who play a key role in advancing the interests of California’s biomedical sector. These highly regarded industry executives provide guidance and help set the policy agenda for the independent, 501(c)(6) trade association.
A distinguished physician-scientist who has held leadership roles in industry, government and academics, Friedman is CEO of City of Hope and director of the institution’s National Cancer Institute-designated comprehensive cancer center. He previously held the role of senior vice president of research and development, medical and public policy, for Pharmacia Corporation. Previously, Friedman served as the U.S. Food and Drug Administration (FDA) deputy commissioner and was later tapped by the Clinton Administration to serve as acting commissioner of the agency. He helped streamline the FDA’s review and approval process and provided oversight of evaluations for drugs, biologics, medical devices and food ingredients. Friedman received his bachelor’s degree from Tulane University and his medical degree from the University of Texas. He completed postdoctoral training at Stanford University and the NCI. He is board certified in internal medicine and medical oncology.
As executive vice president of Thermo Fisher Scientific and president of analytical technologies, Malus is responsible for driving innovation and growth in the company’s analytical technologies, chemical analysis, environmental and process instruments, and biosciences businesses. He joined the company in 1998. In his tenure with the company, he has managed every business that serves the research laboratory market. In 2006, Malus was named senior vice president and president of the company’s customer channels group serving the research, healthcare and safety markets. In 2008, he became president of the laboratory consumables and equipment business. Prior to joining Thermo Fisher, Malus held executive management positions in finance, sales, marketing and business development at Textron Inc. He began his career in the auto industry at Ford Motor Co. and Chrysler Corp. Malus received his bachelor's degree from the University of Michigan and his master’s in business administration from the University of Pittsburgh.
Mas leads the biosciences segment for BD, which includes the Cell Analysis and Advanced Bioprocessing businesses. His role includes the formulation of strategies, policies and programs for the business on a global scale with direct responsibility for the innovation process, sales, marketing, business development, operations, regulatory, talent development and indirect accountability for support functions. Prior to assuming his current role in October 2011, Mas served six years as president of BD Medical – Medical Surgical Systems, the largest of BD Medical’s units focused on commercialization and manufacture of medical devices. Before that, Mas served in several positions for BD in Europe and the U.S., including vice president and general Manager of BD Biosciences in Europe, general manager of core products for BD Biosciences - Discovery Labware in the U.S. and controller for BD Diagnostics in Europe. Before joining BD 20 years ago, Mas served in several financial management roles for Bacardi, Abbott Laboratories, Hercules Inc. and Deloitte. He holds a bachelor’s degree in economics from the Massachusetts Institute of Technology and a bachelor’s degree in management from Northeastern University.
Mason heads up Abbott Diabetes Care, the global diabetes medical device division of Abbott. She was appointed to her current role in May 2008. Prior to that, she served as vice president of Latin America pharmaceuticals, and previously ran international marketing for the division. Mason joined Abbott in 1990. For 15 years, she held a number of positions in Abbott's U.S. pharmaceutical business including vice president of its specialty pharmaceutical businesses, the diabetes/metabolics and oncology franchises, as well as the managed healthcare business. Prior to joining Abbott, Mason worked for Quaker Oats, FMC Corporation and Commonwealth Edison. Mason is an advisory board member of the Healthcare Businesswomen’s Association and BayBio Institute chair. She earned a bachelor's degree in industrial engineering from the University of Michigan and a master's degree in business administration from the University of Chicago.
Yonehiro has been president of Perseid Therapeutics since its launch in 2009. He also served as the company’s CEO until this title was eliminated with the company’s acquisition by Astellas in 2011. Before this, Yonehiro was chief business officer and senior vice president of development programs for Maxygen. Prior to his role at Maxygen, Yonehiro held various senior management positions at GenVec, a biopharmaceutical company. Prior to GenVec, he worked in business development at Cell Genesys, in investment banking at Piper Jaffray and in the technology transfer office at Lawrence Berkeley National Laboratory. He received his bachelor’s degree in individualized studies from the University of Minnesota and his master’s degree in business administration from the Haas School of Business at UC Berkeley.
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.
Editorial note: photos available upon request.